ATE342729T1 - Modifizierter tumor-nekrosefaktor - Google Patents

Modifizierter tumor-nekrosefaktor

Info

Publication number
ATE342729T1
ATE342729T1 AT98904563T AT98904563T ATE342729T1 AT E342729 T1 ATE342729 T1 AT E342729T1 AT 98904563 T AT98904563 T AT 98904563T AT 98904563 T AT98904563 T AT 98904563T AT E342729 T1 ATE342729 T1 AT E342729T1
Authority
AT
Austria
Prior art keywords
tnf
necrosis factor
tumor necrosis
modified tumor
range
Prior art date
Application number
AT98904563T
Other languages
English (en)
Inventor
Mike A Clark
Original Assignee
Phoenix Pharmacologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Pharmacologics Inc filed Critical Phoenix Pharmacologics Inc
Application granted granted Critical
Publication of ATE342729T1 publication Critical patent/ATE342729T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor
AT98904563T 1997-01-15 1998-01-15 Modifizierter tumor-nekrosefaktor ATE342729T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3552197P 1997-01-15 1997-01-15
US681098A 1998-01-14 1998-01-14

Publications (1)

Publication Number Publication Date
ATE342729T1 true ATE342729T1 (de) 2006-11-15

Family

ID=26676095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904563T ATE342729T1 (de) 1997-01-15 1998-01-15 Modifizierter tumor-nekrosefaktor

Country Status (11)

Country Link
US (1) US7785579B2 (de)
EP (1) EP1007082B1 (de)
JP (1) JP4295831B2 (de)
CN (1) CN1168495C (de)
AT (1) ATE342729T1 (de)
AU (1) AU725133B2 (de)
CA (1) CA2277757C (de)
DE (1) DE69836222T2 (de)
DK (1) DK1007082T3 (de)
ES (1) ES2275300T3 (de)
WO (1) WO1998031383A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158923B1 (de) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-uricase Konjugate und Verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
CN1315351A (zh) * 2000-03-24 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人一种组织或发育阶段特异转录因子相关因子11和编码这种多肽的多核苷酸
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
ES2286247T3 (es) * 2001-02-21 2007-12-01 Alavita Pharmaceuticals, Inc. Proteinas anexinicas modificacdas y tratamiento de la trombosis.
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
EP1234583A1 (de) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
WO2005056636A2 (en) 2003-12-03 2005-06-23 Nektar Therapeutics Al, Corporation Method of preparing maleimide functionalized polymers
JP4877225B2 (ja) * 2005-02-18 2012-02-15 日油株式会社 ポリオキシアルキレン誘導体
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
RU2435847C2 (ru) 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
ES2532804T3 (es) 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
KR100886783B1 (ko) * 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
CN101837130B (zh) * 2009-03-20 2013-10-23 北京大学 聚乙二醇-二肽-抗肿瘤药物复合物及其用途
US20100284962A1 (en) * 2009-05-06 2010-11-11 Oncopharmacologics, Inc. Modified tumor necrosis factor-beta
KR101861547B1 (ko) 2009-06-25 2018-07-02 크레알타 파마슈티칼스 엘엘씨 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체­매개 상실을 예측하는 방법 및 키트
WO2014151836A1 (en) * 2013-03-14 2014-09-25 Ran Biotechnologies, Inc. Methods and materials for microorganism capture
KR102352614B1 (ko) 2013-03-14 2022-01-18 랜 바이오테크놀러지스, 인크. 생물제제의 검출을 위한 방법 및 물질
CN105294852B (zh) * 2015-10-27 2019-06-07 岳阳新华达制药有限公司 聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
WO2017177148A1 (en) 2016-04-07 2017-10-12 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5447722A (en) 1983-12-12 1995-09-05 University Of Manitoba Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals
EP0229108B1 (de) * 1985-06-26 1990-12-27 Cetus Corporation Solubilisierung von proteinen für pharmazeutische zusammensetzungen mittels polymerkonjugierung
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
AU4660789A (en) 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
EP0401384B1 (de) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemisch modifizierte granulocytenkolonie erregender faktor
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
DE69836222D1 (de) 2006-11-30
CA2277757C (en) 2008-09-16
DK1007082T3 (da) 2007-02-19
CN1243444A (zh) 2000-02-02
US20060222626A1 (en) 2006-10-05
JP2001511784A (ja) 2001-08-14
EP1007082B1 (de) 2006-10-18
WO1998031383A1 (en) 1998-07-23
CA2277757A1 (en) 1998-07-23
EP1007082A4 (de) 2004-05-12
DE69836222T2 (de) 2007-11-15
EP1007082A1 (de) 2000-06-14
ES2275300T3 (es) 2007-06-01
CN1168495C (zh) 2004-09-29
JP4295831B2 (ja) 2009-07-15
AU6241098A (en) 1998-08-07
US7785579B2 (en) 2010-08-31
AU725133B2 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
ATE342729T1 (de) Modifizierter tumor-nekrosefaktor
ES2175460T3 (es) Compuesto de lipoxinas y su utilizacion en el tratamiento de patologias con proliferacion celular.
EP0933995B8 (de) Verfahren zur behandlung von endothelialen verletzungen
NZ337845A (en) Non-antigenic branched polymer conjugates
DK524187A (da) Aminosyrechelaterede midler til udlevering til specifikke biologiske vaevssteder
GR851626B (de)
EP0293852A3 (de) Organopolysiloxanzusammensetzungen, die funktionelle alpha,beta-ungesättigte Carbonylgruppen enthalten
EA200100954A1 (ru) Производные камптотецина, обладающие противоопухолевой активностью
ATE369146T1 (de) Insulinpreparation mit mannitol
HK1032586A1 (en) Imidazolyl-cyclic acetals
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
ES2120962T3 (es) Composicion antivirica.
GR3015431T3 (en) Use of acetyl L-carnitine in the therapeutic treatment of coma.
SE8000466L (sv) Polymeriska immunreglerade medel
NO984052D0 (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
NO995944D0 (no) Anti-arrytmisk blanding og fremgangsmåter for behandling
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
DK0563127T3 (da) Forbedret behandlingsfremgangsmåde til cancer
ATE91237T1 (de) Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
PT1058544E (pt) Inibicao da actividade do tnf
ES2023552A6 (es) Procedimiento para la preparacion de compuestos de inclusion de nimesulida con ciclodextrina.
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
JPS6461429A (en) Remedy for cancer
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007082

Country of ref document: EP

EEIH Change in the person of patent owner